Spotlight on targeting aminoacyl-tRNA synthetases for the treatment of fungal infections.
This month's Spotlight on... focuses on targeting aminoacyl-tRNA synthetases for the treatment of fungal infections. The emergence of drug-resistant strains of bacterial and fungal pathogens has led to the development of new antibiotic strategies. Aminoacyl-tRNA synthetases, crucial for protein synthesis, represent a new target for the treatment of different infectious diseases.
Ferrer
Elisa
E
D000604:Amino Acyl-tRNA Synthetases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001896:Boron Compounds / Q000494:pharmacology / Q000627:therapeutic use; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003515:Cycloleucine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007533:Isoleucine-tRNA Ligase / Q000037:antagonists & inhibitors; D008826:Microbial Sensitivity Tests; D016712:Mupirocin / Q000494:pharmacology / Q000627:therapeutic use; D009181:Mycoses / Q000188:drug therapy* / Q000378:metabolism; D014009:Onychomycosis / Q000188:drug therapy; D046249:Transfer RNA Aminoacylation / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D001896:Boron Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D004791:Enzyme Inhibitors; D003515:Cycloleucine; D016712:Mupirocin; D000604:Amino Acyl-tRNA Synthetases; D007533:Isoleucine-tRNA Ligase; C114614:2-amino-4-methylenecyclopentane-1-carboxylic acid; C512998:tavaborole